Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study

Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study

Abstract Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor was licensed for the treatment of ALK-positive metastatic non-small cell lung cancer in 2016. However, real-world evidence on the safety and effectiveness of brigatinib in Latin America remains limited. Obje...

Full description

Saved in:
Bibliographic Details
Main Authors: Claudio Martin, Gabriela Ileana Malcervelli, Gastón Lucas Martinengo, Patricio Levit, Patricio Servienti, Elisa Malaver, Laura Brion, Vanesa Patronella, Andrea Zumárraga, Jose Zarba
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-025-00484-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40801-025-00484-z

Similar Items